Advancing medicine through licensing, finished-product supply, and technology transfer across 75+ molecules.
Burrard Pharmaceuticals is a Vancouver-based pharmaceutical licensing, finished-product supply and technology-transfer company, delivering technology transfer, formulation development, and regulatory services since 2005. Manufacture is placed with qualified partner sites named per programme.
We combine deep scientific expertise with regulatory know-how to accelerate your path to market — across biosimilars, oncology injectables, diabetes, respiratory, and emerging therapeutic areas.
Learn More About UsEnd-to-end pharmaceutical services, from licensing to technology transfer.
Seamless transfer of manufacturing processes, analytical methods, and regulatory documentation for 75+ molecules.
AI-assisted formulation optimization for small molecules, biologics, and complex generics.
Complete CTD/eCTD preparation, scoped per programme and territory.
Finished product supplied under exclusive licence from qualified partner sites for injectables, oral solids, ophthalmics, and topicals.
Transfer packages under three scopes, CTD/eCTD dossier work for a named molecule and territory, and post-approval support for licensed programmes. One named programme at a time, scoped in writing.
Any module, any molecule — backed by 20+ years of pharmaceutical expertise.
Spanning oncology, diabetes, respiratory, immunology, cardiovascular, and ophthalmics.
Trastuzumab, Bevacizumab, Rituximab, Pembrolizumab biosimilars, Paclitaxel, Docetaxel, Carboplatin, and more.
Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Insulin Glargine, Insulin Aspart, and more.
Dupilumab, Omalizumab, Secukinumab, Ustekinumab, Fluticasone combinations, and more.
Every product meets the standards of its named manufacturing site. Partner facilities are selected per programme for sterile injectables, complex generics, and next-generation therapeutics, and their current GMP certification is provided with the dossier.
Partner With Us